Hims & Hers Health (NYSE:HIMS) Stock Price Up 10.8% – What’s Next?

Hims & Hers Health, Inc. (NYSE:HIMS)’s share price rose 10.8% during trading on Wednesday . The company traded as high as $29.91 and last traded at $30.3360. Approximately 11,227,575 shares were traded during trading, a decline of 57% from the average session volume of 26,227,777 shares. The stock had previously closed at $27.39.

Key Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: CEO Andrew Dudum rejected the Federal Trade Commission’s privacy and advertising allegations, arguing that the agency misunderstands Hims & Hers’ data-sharing and subscription practices. His comments may have helped ease concerns about the potential business impact of the lawsuit. Hims & Hers Rejects Privacy Allegations While Promising Expanded Patient Access
• Positive Sentiment: Management continues to promote expanded patient access, lower-cost treatment options and a possible AI health coach that could improve medication adherence. These initiatives provide potential long-term growth catalysts, although they are not yet material earnings drivers. Hims & Hers CEO discusses AI health coach
• Positive Sentiment: The company’s Eucalyptus transaction is viewed as a potential avenue for entering new markets and broadening Hims & Hers’ international reach, supporting the growth story. Hims & Hers: Eucalyptus Deal Unlocks New Markets
• Neutral Sentiment: Multiple insider share dispositions were reported, including sales by the CEO, CFO and other executives. Most were non-discretionary transactions or Rule 10b5-1 sales used to cover taxes on vested equity, limiting their value as a signal of weakening management confidence. Hims & Hers insider transactions
• Negative Sentiment: The FTC lawsuit alleges improper handling of private health data, deceptive billing and difficult subscription cancellations. Several law firms have launched related shareholder or fiduciary-duty investigations, increasing potential legal costs, compliance requirements and reputational risk. Berger Montague investigation
• Negative Sentiment: Hims & Hers recently delivered strong revenue growth, but its quarterly loss substantially exceeded analyst expectations. The resulting profitability concerns and ongoing scrutiny of the GLP-1 transition could limit the stock’s upside until execution improves. Analyst questions from the Hims & Hers earnings call

Analyst Upgrades and Downgrades

Several research analysts have weighed in on HIMS shares. Deutsche Bank Aktiengesellschaft boosted their price target on Hims & Hers Health from $25.00 to $26.00 and gave the stock a “hold” rating in a research report on Tuesday, August 11th. Barclays raised their target price on shares of Hims & Hers Health from $29.00 to $39.00 and gave the company an “overweight” rating in a research note on Wednesday, June 17th. Zacks Research upgraded shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a report on Monday, July 13th. Morgan Stanley increased their price target on shares of Hims & Hers Health from $21.00 to $28.00 and gave the company an “equal weight” rating in a research note on Tuesday, August 11th. Finally, Needham & Company LLC boosted their price objective on shares of Hims & Hers Health from $35.00 to $42.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. Four analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $32.43.

Hims & Hers Health Stock Performance

The stock has a market capitalization of $7.06 billion, a P/E ratio of -48.17 and a beta of 2.40. The stock’s 50-day simple moving average is $32.10 and its 200 day simple moving average is $26.05. The company has a debt-to-equity ratio of 4.21, a current ratio of 0.93 and a quick ratio of 0.87.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.32). The company had revenue of $753.21 million during the quarter, compared to the consensus estimate of $698.90 million. Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. Hims & Hers Health’s revenue for the quarter was up 38.2% compared to the same quarter last year. During the same period in the previous year, the company earned $0.17 earnings per share. Research analysts expect that Hims & Hers Health, Inc. will post -0.05 EPS for the current fiscal year.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, COO Michael Chi sold 14,027 shares of the firm’s stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $31.50, for a total transaction of $441,850.50. Following the completion of the sale, the chief operating officer directly owned 432,124 shares in the company, valued at $13,611,906. This trade represents a 3.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Irene Becklund sold 7,573 shares of the business’s stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $30.25, for a total value of $229,083.25. Following the sale, the insider owned 11,280 shares of the company’s stock, valued at approximately $341,220. This represents a 40.17% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 139,947 shares of company stock worth $4,728,621. 11.76% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in HIMS. Versant Capital Management Inc boosted its stake in shares of Hims & Hers Health by 801.2% in the second quarter. Versant Capital Management Inc now owns 748 shares of the company’s stock valued at $26,000 after buying an additional 665 shares during the period. MassMutual Private Wealth & Trust FSB increased its stake in Hims & Hers Health by 70.0% during the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company’s stock worth $27,000 after acquiring an additional 319 shares during the period. Binnacle Investments Inc bought a new position in Hims & Hers Health during the 3rd quarter worth $28,000. Bogart Wealth LLC raised its holdings in Hims & Hers Health by 235.8% in the 4th quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock valued at $29,000 after acquiring an additional 632 shares in the last quarter. Finally, Geneos Wealth Management Inc. bought a new stake in shares of Hims & Hers Health during the 1st quarter valued at $30,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.